Completed PHASE3 INTERVENTIONAL 4-arm NCT05872620

A Study of Orforglipron in Adult Participants With Obesity or Overweight and Type 2 Diabetes (ATTAIN-2)

A Phase 3, Randomized, Double-Blind Study to Investigate the Efficacy and Safety of Once-Daily Oral LY3502970 Compared With Placebo in Adult Participants With Obesity or Overweight and Type 2 Diabetes (ATTAIN-2)

Sponsor: Eli Lilly and Company

Conditions Obesity Overweight Type 2 Diabetes

Interventions Orforglipron Placebo

Updated 16 times since 2023 Last updated: Sep 17, 2025 Started: Jun 5, 2023 Primary completion: Aug 8, 2025 Completion: Aug 8, 2025

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE3 trial investigates Obesity and Overweight and is currently completed. Eli Lilly and Company leads this study, which shows 16 recorded versions since 2023 — indicating substantial longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

16 versions recorded

Oct 2025 — Present [monthly]

Completed PHASE3

Status: Active Not Recruiting → Completed
Sep 2025 — Oct 2025 [monthly]

Active Not Recruiting PHASE3
May 2025 — Sep 2025 [monthly]

Active Not Recruiting PHASE3
Mar 2025 — May 2025 [monthly]

Active Not Recruiting PHASE3
Feb 2025 — Mar 2025 [monthly]

Active Not Recruiting PHASE3

▶ Show 11 earlier versions

Nov 2024 — Feb 2025 [monthly]

Active Not Recruiting PHASE3
Sep 2024 — Nov 2024 [monthly]

Active Not Recruiting PHASE3
Jul 2024 — Sep 2024 [monthly]

Active Not Recruiting PHASE3
Jun 2024 — Jul 2024 [monthly]

Active Not Recruiting PHASE3
May 2024 — Jun 2024 [monthly]

Active Not Recruiting PHASE3
Apr 2024 — May 2024 [monthly]

Active Not Recruiting PHASE3

Status: Recruiting → Active Not Recruiting
Nov 2023 — Apr 2024 [monthly]

Recruiting PHASE3
Oct 2023 — Nov 2023 [monthly]

Recruiting PHASE3
Aug 2023 — Oct 2023 [monthly]

Recruiting PHASE3
Jul 2023 — Aug 2023 [monthly]

Recruiting PHASE3

Status: Not Yet Recruiting → Recruiting
Jun 2023 — Jul 2023 [monthly]

Not Yet Recruiting PHASE3

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Eli Lilly and Company

Data source: Eli Lilly and Company

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Albany, United States , Albuquerque, United States , Athens, Greece , Baltimore, United States , Bangalore, India , Bayamón, Puerto Rico , Beijing, China , Botany, Australia , Box Hill, Australia , Brasília, Brazil and 106 more locations